TherapeuticsMD Inc (TXMD)

5.84
AMEX : Health Care
Prev Close 5.64
Day Low/High 5.63 / 5.86
52 Wk Low/High 4.39 / 9.29
Avg Volume 3.23M
Exchange AMEX
Shares Outstanding 196.58M
Market Cap 1.11B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TherapeuticsMD Announces Fourth Quarter And Full-Year 2016 Financial Results

TherapeuticsMD Announces Fourth Quarter And Full-Year 2016 Financial Results

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its fourth quarter and full-year financial results for 2016.

TherapeuticsMD Enters Oversold Territory

TherapeuticsMD Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TherapeuticsMD Announces Webcast Of Investor Day On March 1

TherapeuticsMD Announces Webcast Of Investor Day On March 1

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, today announced webcast details for its Investor Day on Wednesday, March 1, 2017, in New York City.

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Stocks Under $10 Weekly Summary

We closed out our position in OraSure Technologies for an average gain of 105% gain.

TherapeuticsMD To Host Fourth Quarter And Year End 2016 Financial Results Conference Call And Webcast On February 23

TherapeuticsMD To Host Fourth Quarter And Year End 2016 Financial Results Conference Call And Webcast On February 23

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss its fourth quarter and year end 2016 financial and...

Stocks Under $10 Weekly Summary

We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.

Stocks Under $10 Weekly Summary

We used a price decline to add to our position in TherapeuticsMD this week.

September 15th Options Now Available For TherapeuticsMD (TXMD)

September 15th Options Now Available For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD, Inc. saw new options become available today, for the September 15th expiration.

Adding to TherapeuticsMD on Weakness

We maintain our $12.50 price target on this stock.

Stocks Under $10 Portfolio: Consumer Staples Overbought

Stocks Under $10 Portfolio: Consumer Staples Overbought

This week we'll get regional economic and housing data, a GDP report plus fourth-quarter earnings.

Stocks Under $10 Weekly Summary

We’d look to purchase Builders FirstSource, Jive Software and TherapeuticsMD on near-term declines.

TherapeuticsMD Announces Investor Day On March 1

TherapeuticsMD Announces Investor Day On March 1

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will host an Investor Day on Wednesday, March 1, 2017, in New York City.

Stocks Under $10 Weekly Summary

We would consider adding to TherapeuticsMD on the next market decline and booking profits in ON Semiconductor into a rally.

TherapeuticsMD Announces Publication Of Two Manuscripts On The Rejoice Trial For TX-004HR In Leading Peer-Reviewed Medical Journal

TherapeuticsMD Announces Publication Of Two Manuscripts On The Rejoice Trial For TX-004HR In Leading Peer-Reviewed Medical Journal

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the publication of two manuscripts detailing results of the company's phase 3 Rejoice Trial in Menopause: The Journal of The...

Stocks Under $10 Weekly Summary

We didn't trade in the model portfolio this week, but several of our holdings made big moves so far this year.

TherapeuticsMD Posts Strong Gains

TherapeuticsMD is up 9.7% in the first two trading days of 2017, and we're maintaining our $12.50 price target.

'Mad Money' Lightning Round: Jim Cramer Sees Opportunity in Sirius and Medtronic

'Mad Money' Lightning Round: Jim Cramer Sees Opportunity in Sirius and Medtronic

Sirius, Medtronic and Carlyle could be money makers in 2017, says Jim Cramer.

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.

TherapeuticsMD To Present At 35th Annual J.P. Morgan Healthcare Conference On January 11

TherapeuticsMD To Present At 35th Annual J.P. Morgan Healthcare Conference On January 11

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will present at the 35 th Annual J.

Stocks Under $10 Weekly Summary

We closed out a number of holdings for big gains in 2016, including McDermott, Cott and CECO Environmental.

Stocks Under $10 Weekly Summary

We didn't make any trades this week but are keeping 40% of the portfolio in cash to add names as opportunities arise.

Stocks Under $10 Weekly Summary

We bought more TherapeuticsMD and Yamana Gold using proceeds from the sale of some Orasure shares.

TherapeuticsMD Up on Fresh Buy Rating

Cantor Fitzgerald initiated coverage of the company overnight with $34 price target.

Buying More TherapeuticsMD

We'll put some money to work with TXMD and improve our cost basis.

TherapeuticsMD Announces Participation In 2016 BioFlorida Conference

TherapeuticsMD Announces Participation In 2016 BioFlorida Conference

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company headquartered in Boca Raton, announced the company's participation in the 2016 BioFlorida Conference to be held in Jacksonville from December...

Stocks Under $10 Weekly Summary

We bought shares of TherapeuticsMD but still have a large portion of the portfolio in cash.

Adding to TherapeuticsMD on Weakness

TXMD reported positive clinical data earlier this week.